TargetMol

Mitolactol

Product Code:
 
TAR-T25816
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25816-25mg25mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Mitolactol is an alkylating antineoplastic toxic to bone marrow; utilized in breast cancer, also in combination with other drugs. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors.
CAS:
10318-26-0
Formula:
C6H12Br2O4
Molecular Weight:
307.966
Purity:
0.98
SMILES:
O[C@@H](CBr)[C@@H](O)[C@@H](O)[C@H](O)CBr

Documents

References

1. Jeney A, Kralov?nszky J, Lapis K. [Anticancer drug research in Hungary, 1950-2000]. Magy Onkol. 2017 Dec 18;61(4):375-382. Epub 2017 Nov 30. Hungarian. PubMed PMID: 29257158. 2. Qi L, Ding L, Wang S, Zhong Y, Zhao D, Gao L, Wang W, Lv P, Xu Y, Wang S. A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget. 2016 Oct 18;7(42):69002-69013. doi: 10.18632/oncotarget.10763. PubMed PMID: 27458167; PubMed Central PMCID: PMC5356607. 3. Ishiyama T, Jinguu A, Matsumoto H, Kikuchi J, Suzuki T, Yamakawa M. [A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen]. Gan To Kagaku Ryoho. 2012 Aug;39(8):1287-9. Japanese. PubMed PMID: 22902461. 4. Olasz L, Orsi E, Mark? T, Szalma J. Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC). Cancer Metastasis Rev. 2010 Dec;29(4):607-11. doi: 10.1007/s10555-010-9259-7. Review. PubMed PMID: 20842409.